Holosensor Medical Technology Ltd.
Holosensor Medical Ltd. Is an international leading company focusing on the development of in vitro diagnostic microfluidic systems. The core R& D and production team is composed of returned pH. D., foreign pH. D. And Royal Academician from Cambridge University. The production management team is composed of former senior executives of famous Chinese pharmaceutical enterprises. The company is committed to the rapid screening of rare substances (rare cells, rare proteins) in blood by using microfluidic platform. One of the key technologies is the capture screen of antibodies by microarray filter membrane, which can be used for the high sensitivity, high specificity and rapid screening of many kinds of cells. The company is located in Zhangjiagang City, Suzhou, and has established long-term virtual R& D centers at Cambridge University and Warwick University.
At present, the company mainly provides microfluidic control system development and production in the field of in vitro diagnosis as well as microfluidic technical consultancy services. Its business scope includes: Automatic microdroplet high-speed production intelligent system; Circulating tumor cell rapid screening system; Microbial rapid detection kit; Trace detection kit for misfolded protein in neurodegenerative diseases; Preparation of microcapsules.
It has established cooperative relations with domestic first-line hospitals such as PLA General Hospital, Shanghai Changzheng Hospital, Jiangsu People′s Hospital and the First Affiliated Hospital of Suda, and has carried out extensive product trials in domestic first-line cancer gene detection enterprises, drug sensitive experimental enterprises, animal model enterprises and cancer vaccine enterprises.
It is expected that more than 50 high-end talents will be introduced from 2018 to 2024, including doctoral students from overseas returning schools, domestic doctoral students, and high-skilled professionals above undergraduate level.
At present, the company mainly provides microfluidic control system development and production in the field of in vitro diagnosis as well as microfluidic technical consultancy services. Its business scope includes: Automatic microdroplet high-speed production intelligent system; Circulating tumor cell rapid screening system; Microbial rapid detection kit; Trace detection kit for misfolded protein in neurodegenerative diseases; Preparation of microcapsules.
It has established cooperative relations with domestic first-line hospitals such as PLA General Hospital, Shanghai Changzheng Hospital, Jiangsu People′s Hospital and the First Affiliated Hospital of Suda, and has carried out extensive product trials in domestic first-line cancer gene detection enterprises, drug sensitive experimental enterprises, animal model enterprises and cancer vaccine enterprises.
It is expected that more than 50 high-end talents will be introduced from 2018 to 2024, including doctoral students from overseas returning schools, domestic doctoral students, and high-skilled professionals above undergraduate level.
